The reported statements, read against the company's own industry.
Financials view
Market Capitalization
2.43BCNY
360.61M · vs all stocks (USD)
Updated Aug 19, 2026
Revenue (TTM)
625.70MCNY
92.93M · vs all stocks (USD)
Updated Aug 19, 2026
Profit Margin
-35.71%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Beta
1.09x
vs all stocks
Updated Aug 19, 2026
52-Week Change
-1.80%
vs all stocks
Updated Aug 19, 2026
Market Capitalization
2.43BCNY
360.61M · vs all stocks (USD)
Updated Aug 19, 2026
Enterprise Value
3.69BCNY
547.97M · vs all stocks (USD)
Updated Aug 19, 2026
Forward P/E
15.94x
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Price to Sales (TTM)
4.17x
vs Scientific & Technical Instruments peers
Provider-reported. Market Capitalization ÷ Revenue (TTM) on this page gives 3.88×.Updated Aug 19, 2026
Price to Book (MRQ)
2.47x
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Enterprise to Revenue
5.90x
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Enterprise to EBITDA
-29.19x
vs Scientific & Technical Instruments peers
Provider-reported. Enterprise Value ÷ EBITDA (TTM) on this page gives 57.76×.Updated Aug 19, 2026
Gross Margin
50.04%
vs Scientific & Technical Instruments peers
Provider-reported. Gross Profit (TTM) ÷ Revenue (TTM) on this page gives 37.32%.Updated Aug 19, 2026
Profit Margin
-35.71%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Operating Margin
5.83%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Return on Assets (TTM)
-2.89%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Return on Equity (TTM)
-19.32%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Revenue (TTM)
625.70MCNY
92.93M · vs all stocks (USD)
Updated Aug 19, 2026
Revenue per Share (TTM)
1.26CNYUpdated Aug 19, 2026
Quarterly Revenue Growth
5.10%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Gross Profit (TTM)
233.51MCNY
34.68M · vs all stocks (USD)
Updated Aug 19, 2026
EBITDA (TTM)
63.88MCNY
9.49M · vs all stocks (USD)
Updated Aug 19, 2026
Net Income (TTM)
-223.43MCNY
-33.18M · vs all stocks (USD)
Updated Aug 19, 2026
Quarterly Earnings Growth (YoY)
297.40%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Operating Cash Flow (TTM)
214.96MCNY
31.93M · vs all stocks (USD)
Updated Aug 19, 2026
Levered Free Cash Flow (TTM)
217.90MCNY
32.36M · vs all stocks (USD)
Updated Aug 19, 2026
5-Year Average Dividend Yield
0.65%
vs all stocks
Updated Aug 19, 2026
Payout Ratio
0.00%
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Minority Interest (Equity)
38.24MCNYFY2025 · Dec 31, 2025
Revenue
619.14MCNYFY2025 · Dec 31, 2025
Cost of Goods Sold
352.29MCNYFY2025 · Dec 31, 2025
Gross Profit
266.86MCNYFY2025 · Dec 31, 2025
Operating Income
1.45MCNY
215.86K · vs all stocks (USD)
FY2025 · Dec 31, 2025
Pre-tax Income
-230.16MCNYFY2025 · Dec 31, 2025
Income Tax Expense
11.22MCNYFY2025 · Dec 31, 2025
Net Income
-241.37MCNYFY2025 · Dec 31, 2025
EBIT
-172.71MCNYFY2025 · Dec 31, 2025
EBITDA (Income Statement)
63.88MCNYFY2025 · Dec 31, 2025
Research & Development
41.59MCNYFY2025 · Dec 31, 2025
Selling, General & Administrative
79.26MCNYFY2025 · Dec 31, 2025
Other Operating Expenses
10.65MCNYFY2025 · Dec 31, 2025
Non-operating Interest Income
34.24MCNYFY2025 · Dec 31, 2025
Non-operating Interest Expense
57.45MCNYFY2025 · Dec 31, 2025
EPS (Basic)
-0.4700CNYFY2025 · Dec 31, 2025
EPS (Diluted)
-0.4700CNYFY2025 · Dec 31, 2025
Basic Shares Outstanding
495.39MSharesFY2025 · Dec 31, 2025
Diluted Shares Outstanding
495.39MSharesFY2025 · Dec 31, 2025
Net Income from Continuing Operations
-241.37MCNYFY2025 · Dec 31, 2025
Minority Interests (P&L)
8.54MCNYFY2025 · Dec 31, 2025
Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025
Operating Cash Flow
22.93MCNYFY2025 · Dec 31, 2025
Free Cash Flow
16.08MCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents (End of Period)
116.35MCNYFY2025 · Dec 31, 2025
Starting Profit (CF Statement)
-241.37MCNYFY2025 · Dec 31, 2025
Other Non-cash Items
62.24MCNYFY2025 · Dec 31, 2025
Change in Accounts Receivable (CF)
178.60MCNYFY2025 · Dec 31, 2025
Change in Other Assets/Liabilities
23.45MCNYFY2025 · Dec 31, 2025
Capital Expenditures
6.84MCNYFY2025 · Dec 31, 2025
Net Acquisitions
0.00CNYFY2025 · Dec 31, 2025
Purchase of Investments
0.00CNYFY2025 · Dec 31, 2025
Sale of Investments
75.06KCNYFY2025 · Dec 31, 2025
Net Investing Cash Flow
6.92MCNYFY2025 · Dec 31, 2025
Long-term Debt Issuance
117.52MCNYFY2025 · Dec 31, 2025
Long-term Debt Payments
-234.87MCNYFY2025 · Dec 31, 2025
Common Dividends Paid
-57.51MCNYFY2025 · Dec 31, 2025
Other Financing Charges
-2.32MCNYFY2025 · Dec 31, 2025
Net Financing Cash Flow
-177.17MCNYFY2025 · Dec 31, 2025
Shares Outstanding
495.51MSharesUpdated Aug 19, 2026
Float Shares
352.16MSharesUpdated Aug 19, 2026
% Held by Insiders
28.58%
vs all stocks
Updated Aug 19, 2026
% Held by Institutions
5.81%
vs all stocks
Updated Aug 19, 2026
Total Cash (MRQ)
141.21MCNY
20.97M · vs all stocks (USD)
Updated Aug 19, 2026
Total Cash per Share (MRQ)
0.2850CNYUpdated Aug 19, 2026
Total Debt (MRQ)
1.19BCNY
176.64M · vs all stocks (USD)
Updated Aug 19, 2026
Total Debt to Equity (MRQ)
1.09x
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Current Ratio (MRQ)
3.21x
vs Scientific & Technical Instruments peers
Updated Aug 19, 2026
Book Value per Share (MRQ)
2.13CNYUpdated Aug 19, 2026
Total Assets
3.01BCNY
446.96M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Total Current Assets
2.71BCNYFY2025 · Dec 31, 2025
Total Liabilities
1.93BCNYFY2025 · Dec 31, 2025
Total Non-current Assets
298.17MCNYFY2025 · Dec 31, 2025
Total Non-current Liabilities
1.07BCNYFY2025 · Dec 31, 2025
Total Current Liabilities
859.19MCNYFY2025 · Dec 31, 2025
Cash
120.24MCNYFY2025 · Dec 31, 2025
Cash Equivalents
642.59KCNYFY2025 · Dec 31, 2025
Cash & Cash Equivalents
120.88MCNYFY2025 · Dec 31, 2025
Accounts Receivable
478.58MCNYFY2025 · Dec 31, 2025
Inventory
292.72MCNYFY2025 · Dec 31, 2025
Accounts Payable
360.38MCNYFY2025 · Dec 31, 2025
Short-term Debt
137.95MCNYFY2025 · Dec 31, 2025
Other Current Liabilities
33.64MCNYFY2025 · Dec 31, 2025
Long-term Debt
1.05BCNYFY2025 · Dec 31, 2025
Other Non-current Liabilities
12.61MCNYFY2025 · Dec 31, 2025
Common Stock (Book)
495.51MCNYFY2025 · Dec 31, 2025
Retained Earnings
-293.18MCNYFY2025 · Dec 31, 2025
Total Shareholders' Equity
1.08BCNY
160.54M · vs all stocks (USD)
FY2025 · Dec 31, 2025
Treasury Stock
0.00CNYFY2025 · Dec 31, 2025
52-Week Low
4.00CNYUpdated Aug 19, 2026
52-Week High
9.11CNYUpdated Aug 19, 2026
52-Week Change
-1.80%
vs all stocks
Updated Aug 19, 2026
Beta
1.09x
vs all stocks
Updated Aug 19, 2026
50-Day MA
5.28CNYUpdated Aug 19, 2026
200-Day MA
5.43CNYUpdated Aug 19, 2026
Avg 10-Day Volume
12.91MSharesUpdated Aug 19, 2026
Avg 30-Day Volume
15.23MSharesUpdated Aug 19, 2026
Diluted EPS (TTM)
-0.4500CNYUpdated Aug 19, 2026
1 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Debt-to-equity is 1.09×, higher than 95% of its Scientific & Technical Instruments peers (median 0.13×)Significant